Brief: Cyclerion Reports Positive Topline Clinical Data For CY6463

Korsana Biosciences

28/07/2022 12:31

July 28 (Reuters) - Cyclerion Therapeutics Inc  CYCN.O :
    * CYCLERION THERAPEUTICS ANNOUNCES POSITIVE TOPLINE CLINICAL
DATA
FOR CY6463 IN PATIENTS WITH COGNITIVE IMPAIRMENT ASSOCIATED WITH
SCHIZOPHRENIA (CIAS)
    * CYCLERION - DATA SHOW POSITIVE EFFECTS OF CY6463 ON
COGNITION &
INFLAMMATION AFTER 2 WEEKS OF DOSING IN PATIENTS WITH STABLE
SCHIZOPHRENIA ON STANDARD OF CARE
    * CYCLERION THERAPEUTICS - ORAL, ONCE-DAILY CY6463 WELL
TOLERATED,
NO REPORTS OF SERIOUS ADVERSE EVENTS OR TREATMENT
DISCONTINUATION DUE TO ADVERSE EVENTS

Source text for Eikon:  ID:nGNX2x1kh0 
Further company coverage:  CYCN.O 

 ((Reuters.Briefs@thomsonreuters.com;))